Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS.
Cholesteatoma
/ genetics
Ear Canal
/ pathology
Ear, Middle
/ pathology
Gene Expression Regulation
/ drug effects
Humans
Inflammation
/ genetics
Inflammation Mediators
/ metabolism
Lipopolysaccharides
/ pharmacology
Models, Biological
NF-kappa B
/ metabolism
Rhodobacter sphaeroides
/ chemistry
Signal Transduction
/ drug effects
Skin
/ pathology
Spheroids, Cellular
/ pathology
Stem Cells
/ drug effects
Toll-Like Receptor 4
/ antagonists & inhibitors
Tumor Necrosis Factor-alpha
/ pharmacology
IL-6
LPS-RS
NF-κB
TRL4
cholesteatoma
inflammation
stem cells
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
14 01 2020
14 01 2020
Historique:
received:
11
11
2019
revised:
19
12
2019
accepted:
09
01
2020
entrez:
18
1
2020
pubmed:
18
1
2020
medline:
16
1
2021
Statut:
epublish
Résumé
Cholesteatoma is a severe non-cancerous lesion of the middle ear characterized by massive inflammation, tissue destruction, and an abnormal growth of keratinized squamous epithelium. We recently demonstrated the presence of pathogenic stem cells within cholesteatoma tissue, unfortunately their potential roles in regulating disease-specific chronic inflammation remain poorly understood. In the presented study, we utilized our established human in vitro cholesteatoma stem cell model for treatments with lipopolysaccharides (LPS), tumor necrosis factor α (TNFα), and the TLR4-antagonist LPS from
Identifiants
pubmed: 31947538
pii: cells9010199
doi: 10.3390/cells9010199
pmc: PMC7017370
pii:
doi:
Substances chimiques
Inflammation Mediators
0
Lipopolysaccharides
0
NF-kappa B
0
Toll-Like Receptor 4
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Pediatr Otorhinolaryngol. 2013 May;77(5):674-6
pubmed: 23380629
J Infect Dis. 1999 Nov;180(5):1584-9
pubmed: 10515819
J Pharmacol Exp Ther. 2003 Mar;304(3):1093-102
pubmed: 12604686
Sci Rep. 2015 Jun 23;5:11542
pubmed: 26100219
Am J Physiol Lung Cell Mol Physiol. 2005 Aug;289(2):L329-37
pubmed: 15833764
Blood. 1996 Apr 15;87(8):3410-7
pubmed: 8605359
Laryngoscope. 2003 Jun;113(6):1022-6
pubmed: 12782815
J Dermatol Sci. 2006 Sep;43(3):159-69
pubmed: 16887338
Cell. 2007 Sep 7;130(5):906-17
pubmed: 17803912
Am J Otolaryngol. 1991 Sep-Oct;12(5):254-8
pubmed: 1811420
Oncogene. 2006 Oct 30;25(51):6680-4
pubmed: 17072321
Expert Opin Drug Metab Toxicol. 2011 Apr;7(4):479-94
pubmed: 21323610
J Gastroenterol Hepatol. 2009 Jun;24(6):1089-94
pubmed: 19226379
PLoS One. 2013 Nov 11;8(11):e78887
pubmed: 24324544
ORL J Otorhinolaryngol Relat Spec. 2011;73(2):93-9
pubmed: 21311206
Cell Res. 2010 Jan;20(1):24-33
pubmed: 19997086
Otol Neurotol. 2003 Sep;24(5):709-13
pubmed: 14501443
Eur Arch Otorhinolaryngol. 2004 Jan;261(1):6-24
pubmed: 12835944
Laryngoscope. 2015 Jan;125(1):234-40
pubmed: 25123251
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80
pubmed: 16488332
JAMA. 2013 Mar 20;309(11):1154-62
pubmed: 23512062
Biochim Biophys Acta. 2013 Dec;1833(12):2866-2878
pubmed: 23872422
J Immunol. 2005 Nov 15;175(10):6465-72
pubmed: 16272300
Mediators Inflamm. 2005 Aug 31;2005(4):210-5
pubmed: 16192670
Int J Mol Med. 2014 Jun;33(6):1431-40
pubmed: 24676340
Adv Clin Exp Med. 2013 Mar-Apr;22(2):209-17
pubmed: 23709377
Acta Otolaryngol. 1990 Nov-Dec;110(5-6):410-5
pubmed: 1704675
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
BMJ. 2011 Mar 03;342:d1088
pubmed: 21372073
Otolaryngol Head Neck Surg. 1995 Mar;112(3):359-68
pubmed: 7532849
Cell Stem Cell. 2011 May 6;8(5):486-98
pubmed: 21549325
Clin Sci (Lond). 2016 Aug 1;130(15):1339-52
pubmed: 27129189
Eur Arch Otorhinolaryngol. 2014 Feb;271(2):265-73
pubmed: 23463347
Mol Cell Biol. 1993 Oct;13(10):6231-40
pubmed: 8413223
Curr Opin Otolaryngol Head Neck Surg. 2009 Oct;17(5):339-45
pubmed: 19745736
BMC Genomics. 2003 Nov 25;4(1):46
pubmed: 14641910
Acta Otolaryngol. 1996 Mar;116(2):302-6
pubmed: 8725537
Acta Otorhinolaryngol Ital. 2009 Aug;29(4):197-202
pubmed: 20161877
Sci Rep. 2015 Dec 07;5:16683
pubmed: 26639190
Eur J Pharm Sci. 2010 Jan 31;39(1-3):110-5
pubmed: 19931387
J Laryngol Otol. 2010 Jun;124(6):587-93
pubmed: 20156369
Am J Otol. 2000 Nov;21(6):786-92
pubmed: 11078064
Sci Rep. 2018 Apr 18;8(1):6204
pubmed: 29670222
Mol Cell Biol. 1990 May;10(5):2327-34
pubmed: 2183031
Mediators Inflamm. 2010;2010:796315
pubmed: 20414373
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Stem Cells Dev. 2012 Mar 20;21(5):742-56
pubmed: 22128806
PLoS One. 2012;7(12):e52718
pubmed: 23285167
Biochem Biophys Res Commun. 2013 May 10;434(3):600-5
pubmed: 23583403
Acta Otolaryngol. 2013 Feb;133(2):165-73
pubmed: 23157229
Mol Med Today. 1999 Oct;5(10):439-47
pubmed: 10498912
Eur Cell Mater. 2011 Dec 17;22:403-19
pubmed: 22179938